Detalhe da pesquisa
1.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet
; 398(10318): 2258-2276, 2021 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34863358
2.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
3.
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2.
EClinicalMedicine
; 56: 101823, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36684396
4.
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
J Infect
; 87(1): 18-26, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37085049
5.
Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.
Clin Transl Sci
; 15(2): 524-534, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34670021
6.
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Lancet Infect Dis
; 22(8): 1131-1141, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35550261
7.
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
J Infect
; 84(6): 795-813, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405168
8.
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
J Infect
; 86(5): 540-541, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37055303